Form 4: Director Timothy Coughlin Increases Stake in Vir Biotech
Statement of Changes in Beneficial Ownership
Director Timothy Coughlin acquired 16,000 shares of restricted stock units and 32,000 stock options in Vir Biotechnology, Inc.
Summary
- Director Timothy Coughlin was granted 16,000 restricted stock units (RSUs) and 32,000 stock options on June 9, 2026.
- The RSUs consist of two separate grants of 8,000 shares each with varying vesting schedules.
- The stock options were granted with an exercise price of $8.51 per share.
- All transactions were conducted under the Issuer's Equity Incentive Plan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices rather than a change in company strategy or financial performance.
Positives
- Director alignment with shareholder interests through increased equity ownership.
- Long-term incentive structure via multi-year vesting schedules for RSUs and options.
Negatives
- Dilutive impact of new equity grants on existing shareholders.
Risks
- Market price volatility affecting the value of granted options.
- Vesting conditions dependent on future service or annual meeting dates.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that director equity grants are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.
Comparison to Industry Standards
- The use of RSUs and stock options as part of director compensation is consistent with standard practices for mid-cap biotechnology firms.
- Vesting schedules tied to annual meetings or multi-year service are common benchmarks for executive and director retention.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Grant | Grant of RSUs and stock options to Director Timothy Coughlin. | 06/09/2026 | Increases director's beneficial ownership in the company. |
Stakeholder Impact
- Shareholders: Minor dilution from new equity issuance.
- Director: Increased financial alignment with company performance.
Next Steps
- Vesting of initial RSU and option tranches on June 9, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Date of earliest transaction and grant date for RSUs and options. |
| 06/09/2027 | Initial vesting date for a portion of RSUs and stock options. |
| 06/08/2036 | Expiration date for the granted stock options. |
Keywords
Vir Biotechnology, VIR, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.